Lerouge Delphine, Touboul Emmanuel, Lefranc Jean-Pierre, Genestie Catherine, Moureau-Zabotto Laurence, Blondon Jean
Department of Radiation Oncology, Tenon Hospital A.P.-H.P., 4 rue de la Chine, 75950 Paris cedex 20, France.
Int J Radiat Oncol Biol Phys. 2004 Jul 15;59(4):1062-73. doi: 10.1016/j.ijrobp.2003.12.034.
To evaluate our updated data concerning survival and locoregional control in a prospective study of locally advanced noninflammatory breast cancer (LABC) after primary chemotherapy (CT) followed by external preoperative irradiation (RT).
Between 1982 and 1998, 120 patients (75 Stage IIIA, 41 Stage IIIB, and 4 Stage IIIC according to AJCC staging system 2002) were treated by four courses of induction CT with anthracycline-containing combinations followed by preoperative RT (45 Gy to the breast and nodal areas) and a fifth course of CT. Three different locoregional approaches were proposed depending on tumor characteristics and tumor response. After completion of local therapy, all patients received a sixth course of CT and a maintenance adjuvant CT regimen without anthracycline. The median follow-up from the beginning of treatment was 140 months.
Mastectomy and axillary dissection were performed in 49 patients (with residual tumor larger than 3 cm in diameter or located behind the nipple or with bifocal tumor), and conservative treatment in 71 patients (39 achieved clinical complete response or partial response >90% and received additional radiation boost to initial tumor bed; 32 had residual mass < or =3 cm in diameter and were treated by wide excision and axillary dissection followed by a boost to the excision site). Ten-year actuarial local failure rate was 13% after RT alone, 23% after wide excision and RT, and 4% after mastectomy (p = 0.1). After multivariate analysis, possibility of breast-conserving therapy was related to initial tumor size (<6 cm vs. > or =6 cm in diameter, p = 0.002). Ten-year overall metastatic disease-free survival rate was 61%. After multivariate analysis, metastatic disease-free survival rates were significantly influenced by clinical stage (Stage IIIA-B vs. IIIC, p = 0.0003), N-stage (N0 vs. N1-2a, and 3c, p = 0.017), initial tumor size (<6 cm vs. > or =6 cm in diameter, p = 0.008), and tumor response after induction CT and preoperative RT (clinically complete response + partial response vs. nonresponder, p = 0.0015). In the nonconservative breast treatment group, of the 32 patients with no change in clinical tumor size after induction CT, the 10-year metastatic disease-free survival rate was 59% with only one local relapse. Arm lymphedema was noted in 17% (14 of 81) after axillary dissection and in 2.5% (1 of 39) without axillary dissection. Cosmetic results were satisfactory in 70% of patients treated by RT alone and in 51.5% of patients after wide excision and RT.
Despite the poor prognosis of patients with LABC resistant to primary anthracycline-based regimen, aggressive locoregional management using preoperative RT and mastectomy with axillary dissection offers a possibility of long-term survival with low local failure rate for patients without extensive nodal disease. On the other hand, the rate of local failure seems to be high in patients with clinical partial tumor response after induction CT and breast-conserving treatment combining preoperative RT and large wide excision.
在一项关于局部晚期非炎性乳腺癌(LABC)的前瞻性研究中,评估我们关于生存及局部区域控制的最新数据,该研究采用了术前辅助化疗(CT)后行外照射术前放疗(RT)。
1982年至1998年间,120例患者(根据2002年美国癌症联合委员会分期系统,75例为IIIA期,41例为IIIB期,4例为IIIC期)接受了含蒽环类药物联合方案的4个疗程诱导化疗,随后进行术前放疗(乳腺及腋窝区域45 Gy)及第5个疗程化疗。根据肿瘤特征和肿瘤反应提出了3种不同的局部区域治疗方法。局部治疗完成后,所有患者接受第6个疗程化疗及不含蒽环类药物的维持辅助化疗方案。从治疗开始的中位随访时间为140个月。
49例患者(残留肿瘤直径大于3 cm或位于乳头后方或为双灶性肿瘤)行乳房切除术及腋窝淋巴结清扫术,71例患者接受保乳治疗(39例达到临床完全缓解或部分缓解>90%并对初始瘤床追加放疗;32例残留肿块直径≤3 cm,行广泛切除及腋窝淋巴结清扫术,随后对切除部位追加放疗)。单纯放疗后10年精算局部失败率为13%,广泛切除加放疗后为23%,乳房切除术后为4%(p = 0.1)。多因素分析后,保乳治疗的可能性与初始肿瘤大小相关(直径<6 cm与≥6 cm,p = 0.002)。10年无远处转移疾病生存率为61%。多因素分析后,无远处转移疾病生存率受临床分期(IIIA - B期与IIIC期,p = 0.0003)、N分期(N0与N1 - 2a及3c,p = 0.017)、初始肿瘤大小(直径<6 cm与≥6 cm,p = 0.008)以及诱导化疗和术前放疗后的肿瘤反应(临床完全缓解 + 部分缓解与无反应者,p = 0.0015)显著影响。在非保乳治疗组中,诱导化疗后临床肿瘤大小无变化的32例患者中,10年无远处转移疾病生存率为59%,仅1例局部复发。腋窝淋巴结清扫术后17%(81例中的14例)出现上肢淋巴水肿,未行腋窝淋巴结清扫术的患者中2.5%(39例中的1例)出现。单纯放疗治疗的患者中70%美容效果满意,广泛切除加放疗后的患者中51.5%美容效果满意。
尽管对基于蒽环类药物的初始方案耐药的LABC患者预后较差,但对于无广泛淋巴结疾病的患者,采用术前放疗及乳房切除加腋窝淋巴结清扫的积极局部区域治疗可提供低局部失败率的长期生存可能性。另一方面,诱导化疗后临床部分肿瘤反应且保乳治疗联合术前放疗及广泛切除的患者局部失败率似乎较高。